Answer to Written Question: Risks posed by the AstraZeneca vaccine

(Source: European Parliament)

EN

E-001703/2021

Answer given by Ms Kyriakides

on behalf of the European Commission

(1.6.2021)

The European Medicines Agency Committee for Medicinal Products for Human Use is carrying out further analysis and stratification of data on very rare blood clots across different age groups and different rates of infection[1]. At present, the Committee recommends to continue giving a second dose of Vaxzevria in line with the product information[2]. Further data and results will be published when this scientific assessment is concluded.

Supporting equal and global access to a safe and efficient vaccine for everyone in the world is a priority for the Commission. The Commission collaborates with the World Health Organization (WHO) and is a member of the COVAX Facility, supporting the global effort to produce and distribute vaccines to all in need, in particular to low and middle income countries.

The Commission has urged EU Member States to increase their capacities for genome sequencing to detect variants of severe acute respiratoy syndrome coronavirus 2 (SARS CoV-2). On 25 February 2021, the Commission announced that EUR 200 million would be made available to support such efforts, particularly in the context of the HERA Incubator[3]. The European Centre for Disease Prevention and Control in collaboration with the WHO is providing guidance on the detection and identification of SARS-CoV variants, including on genome sequencing, and is arranging and funding the genome sequencing of COVID-19 samples for those Member States with limited capacities[4].


[1] The European Commission requested this review under Article 5(3) of Regulation 726/2004 following an informal meeting of EU health ministers on 7 April 2021. https://www.ema.europa.eu/en/documents/referral/letter-commissioner-kyriakides-asking-ema-follow-vaxzevria-opinion-after-council-discussion_en.pdf

[2] https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-benefits-risks-context

[3] COM(2021) 78 HERA Incubator: Anticipating together the threat of COVID-19 variants

[4] European Centre for Disease Prevention and Control (ECDC), WHO Regional Office for Europe. Methods for the detection and identification of SARS-CoV-2 variants. 3 March 2021. ECDC and WHO Regional Office for Europe: Stockholm and Copenhagen; 2021 https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants-WHO-ECDC.pdf

%d bloggers like this: